PharmAthene, Inc s trend and data analysis indicates that the stock price has dropped -74.62% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -71.55% . Looking at the past 52 week period, the stock price is down -52.31% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of PharmAthene, Inc has a positive value of 30.25 compared to overall market.PharmAthene, Inc. is having a Relative Strength Index of 34.01 which indicates the stock is not yet over sold or over bought based on the technical indicators.
PharmAthene, Inc (NYSEMKT:PIP) has tumbled 5.32% during the past week and has dropped 20.67% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 5.55%. PharmAthene, Inc (NYSEMKT:PIP) has underperformed the index by 21.58% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. PharmAthene, Inc (NYSEMKT:PIP) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0332 points or 3.87% at $0.825 with 1,877,326 shares getting traded. Post opening the session at $0.85, the shares hit an intraday low of $0.7921 and an intraday high of $0.8543 and the price was in this range throughout the day. The company has a market cap of $57 million and the number of outstanding shares has been calculated to be 68,815,195 shares. The 52-week high of PharmAthene, Inc (NYSEMKT:PIP) is $3.5 and the 52-week low is $0.47.
Company has reported several Insider transactions to the SEC, on Apr 15, 2016, Eric I Richman (director) sold 329,354 shares at 2.20 per share price.On Mar 23, 2015, Peter Steven St (director) purchased 25,000 shares at 1.65 per share price.On Jan 9, 2015, Linda L Chang (SVP, CFO & Secretary) sold 29,600 shares at 2.10 per share price.
PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthenes lead programs include Valortim and Protexia.